Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy

Further Publications

Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma

BMC Gastroenterol

Chen C, Ren Y, Li Y, Jiang S, Dong X, Zhou G

doi: 10.1186/s12876-025-04258-3

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Gastrointestinal Cancer

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Lancet

Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J

doi: 10.1016/S0140-6736(26)01252-3

Hepatitis

A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C

J Hepatol

Llibre JM, Boesecke C, Moon J, Lank PM, Miller MG, Fredrick LM, Welhaven A, Semizarov D, Marcinak J, Gentile I, Reiberger T, Puoti M

doi: 10.1016/j.jhep.2025.11.009

Esophagus Diseases

A MACHINE-BASED LEARNING MODEL FOR RECURRENCE PREDICTION AND TIMING AFTER ENDOSCOPIC ERADICATION THERAPY FOR BARRETT'S ESOPHAGUS

Clin Gastroenterol Hepatol

Akshintala V, Han S, Yan Y, Bisschops R, Brennan C, Cai Y, Codipilly DC, Cotton C, Early D, Edmundowicz SA, Eluri S, Gallegos J, Goyal R, Hammad HT, Haidry R, Hollander T, Husain K, Iyer PG, Jojo J, Kushnir V, Komanduri S, Leggett C, Lovat L, Muthusamy VR, Rastogi A, Seewald S, Shaheen NJ, Thaker A, Vantanasiri K, Jones C, Wani S

doi: 10.1016/j.cgh.2026.03.026

Gastrointestinal Cancer

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Eur J Cancer

Vo-Quang E, Campani C, Allaire M, Bouattour M, Regnault H, Marra F, Sutter O, Leroy V, Trepo E, Mouri S, Thabut D, Ozenne V, Sidali S, Hollande C, Boros C, Nahon P, Ganne-Carrié N, Lequoy M, Amaddeo G, Nault JC, Paris Liver Cancer Group

doi: 10.1016/j.ejca.2026.116704

Hepatology

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)

Hepatology

Nahon P, Ziol M, Pan L, Portal JJ, Oberti F, Aube C, Blanc JF, Trillaud H, Merle P, Rode A, Assenat E, Guiu B, Lequoy M, Cornelis F, Bouattour M, Talib Z, Tibi A, Zeng Q, Bouda Y, Ganne-Carrié N, Sutter O, Sutton A, Guyot E, Barget N, Zucman-Rossi J, Campani C, Bamba-Funck J, Calderaro J, Nault JC, Vicaut E, Seror O

doi: 10.1097/HEP.0000000000001764

Hepatitis

EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection

Gut

Tang S, Huang T, Tang R, Lin K, Luo C, Shen Y, Zhang K, Tang Y, Kong J, Chen Z, Fu J, Lin Q, Guo L, Wu Y, Li Y, Zhang J, Sun Z, You P, Zhang D, Chen Y, Lin X, Zhong C, Lin Z, Liu H, Huang Z, Zhou W, Dong P, Liu X, Zeng H, Qi X, Zeng Y

doi: 10.1136/gutjnl-2025-335449

Gastrointestinal Cancer

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort

J Clin Oncol

Moon AM, Yanagihara TK, Dawson LA, Yu JI, Lawrence TS, Kim TH, Yan M, Iwata H, Nabavizadeh N, Apisarnthanarax S, Dunne EM, Lock MI, Chuong MD, Chiang CL, Scorsetti M, Katoh N, Sioshansi S, Numata K, Liu HY, Iwamoto H, Wakatsuki M, Chen Y, Pollom EL, Gkika E, Jabbour SK, Munoz-Schuffenegger P, Dutta D, Hajj C, Ueno M, Hallemeier CL, Feldman AM, Méndèz Romero A, Tan X, Molla M, Tepper JE, Torres F, Reig M, EBRT Collaboration Group

doi: 10.1200/JCO-25-02399

Related content

Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C

A MACHINE-BASED LEARNING MODEL FOR RECURRENCE PREDICTION AND TIMING AFTER ENDOSCOPIC ERADICATION THERAPY FOR BARRETT'S ESOPHAGUS

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)

EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort